Committed to Research

Respiratory Medicine Research banner

Department of Respiratory and Sleep Medicine – Westmead Hospital

Director: Prof John Wheatley

Mission Statement
The purpose of the Department of Respiratory and Sleep Medicine is to deliver effective respiratory health outcomes for our community through the development of strong, productive partnerships and a commitment to excellence in the advancement and dissemination of knowledge in the fields of respiratory and sleep medicine.

The Department functions as a major educational facility for resident staff, students, physicians and general practitioners.

The Department has established itself both locally and internationally as outstanding in terms of the productivity of original research, particularly in the fields of upper airway physiology, and mechanics of chest wall muscles, and cystic fibrosis.

The Department has a clinical trials unit which assesses the effectiveness of new medications with a view to improving health outcomes for people with respiratory and sleep problems.

Clinical Trials

We operate Clinical Trials in the following areas:
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Bronchiectasis
  • Cystic Fibrosis
  • Sleep Apnoea
  • Insomnia
  • Pulmonary Arterial Hypertension
  • Idiopathic Pulmonary Fibrosis (IPF)

 

Current Recruiting Clinical Trials

We are always looking for patients who would be happy to participate in clinical trials. The trials that are currently recruiting are:

Asthma Study

NAVIGATOR – A multicentre, placebo controlled, phase 3 study to evaluate the efficacy and safety of Tezepelumab in adults with severe uncontrolled asthma. This is a 12 month placebo controlled study with monthly visits to the clinic. All travel and parking expenses will be compensated for.

Asthma Study

NAVIGATOR – A multicentre, placebo controlled, phase 3 study to evaluate the efficacy and safety of Tezepelumab in adults with severe uncontrolled asthma. This is a 12 month placebo controlled study with monthly visits to the clinic. All travel and parking expenses will be compensated for.

Pulmonary Arterial Hypertension (PAH)

PULSAR – A multicentre, placebo controlled, phase 2 study to compare the efficacy and safety of Sotatercept when added to standard of care for the treatment of PAH. This study is a 24 week placebo controlled study with visits to the clinic every 3 weeks. Participants who complete the 24 week study will be eligible to continue into the 18 month extension period to receive open label study drug. All travel and parking expenses will be compensated for.

Non-CF Bronchiectasis

PROMIS 1 – A multicentre, placebo controlled, phase 3 study to investigate the efficacy and safety of inhaled colistemethate sodium in the treatment of participants with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa. This is a 12 month placebo controlled study with visits to the clinic once every 3 months. All travel and parking expenses will be compensated for.

Contact for more information regarding trial participation:

Tracey Burns - Clinical Research Manager
Tracey.burns@health.nsw.gov.au
8890 7785

 

Looking for General
Orientation information?

See more